Navarro-Compán V., Puig L., Vidal S., Ramírez J., Llamas-Velasco M., Fernández-Carballido C., Almodóvar R., Pinto J.A., Galíndez-Aguirregoikoa E., Zarco P., Joven B., Gratacós J., Juanola X., Blanco R., Arias-Santiago S., Sanz Sanz J., Queiro R., Canete, JD. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1191782. PMID:37600764. IF:5.700(Q1/3D).

Rusinol, L, Carmona-Rocha E., Puig L.. Psoriasis: a focus on upcoming oral formulations. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2023; 32(7)DOI:10.1080/13543784.2023.2242767. PMID:37507233. IF:4.900(Q1/2D).

Sahuquillo-Torralba A., Hospital-Gil M., Vilarrasa-Rull E., Llamas-Velasco M., Rivera R., Carrascosa J.M., de la Cueva-Dovao P., Armesto-Santos S., Ruíz-Villaverde R., Velasco-Pastor M., Magdaleno-Tapial J., Yanguas-Bayona J.I., Ribera-Pibernat M., Salgado-Boquete L., Herranz-Pinto P., Romero-Mate A., Martínez-Lorenzo E., López-Estebaranz J.L., Ballescá-López F., Botella-Estrada R.. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population. AUSTRALASIAN JOURNAL OF DERMATOLOGY. 2023; DOI:10.1111/ajd.14130. PMID:37435962. IF:2.200(Q2/5D).

Kirkham, BW, Egeberg, A, Behrens, F, Pinter, A, Merola, JF, Holzkaemper, T, Gallo, G, Ng, KJ, Bolce, R, Schuster, C, Nash, P, Puig, L. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Rheumatology and Therapy. 2023; 10(5)DOI:10.1007/s40744-023-00553-1. PMID:37400681. IF:2.900(Q2/4D).